Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TGTX 
TG Therapeutics Inc (TGTX)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TGTX (5-star) is a REGULAR-BUY. BUY since 18 days. Profits (-1.80%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 223.03% | Avg. Invested days 35 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.93B USD | Price to earnings Ratio 251.67 | 1Y Target Price 42.83 |
Price to earnings Ratio 251.67 | 1Y Target Price 42.83 | ||
Volume (30-day avg) 3065636 | Beta 2.3 | 52 Weeks Range 12.93 - 43.32 | Updated Date 04/1/2025 |
52 Weeks Range 12.93 - 43.32 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.11% | Operating Margin (TTM) 27.68% |
Management Effectiveness
Return on Assets (TTM) 5.78% | Return on Equity (TTM) 12.22% |
Valuation
Trailing PE 251.67 | Forward PE 27.17 | Enterprise Value 5872133206 | Price to Sales(TTM) 18.02 |
Enterprise Value 5872133206 | Price to Sales(TTM) 18.02 | ||
Enterprise Value to Revenue 17.85 | Enterprise Value to EBITDA 117.67 | Shares Outstanding 157071008 | Shares Floating 134539735 |
Shares Outstanding 157071008 | Shares Floating 134539735 | ||
Percent Insiders 9.38 | Percent Institutions 62.73 |
Analyst Ratings
Rating 4.44 | Target Price 40.88 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TG Therapeutics Inc
Company Overview
History and Background
TG Therapeutics, Inc. was founded in 1993 and is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Core Business Areas
- Hematological Oncology: Focuses on developing and commercializing therapies for B-cell malignancies such as lymphoma and leukemia.
- Autoimmune Diseases: Expanding focus on developing therapies for autoimmune diseases. This segment is currently more limited.
Leadership and Structure
Michael S. Weiss is the Executive Chairman and CEO. The company has a typical structure with research, development, commercial, and administrative departments.
Top Products and Market Share
Key Offerings
- Ublituximab (Briumvi): An anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis (RMS). Revenue and market share data are still developing. Competitors include Ocrevus (Roche), Kesimpta (Novartis), and Mayzent (Novartis).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in oncology and autoimmune disease, is highly competitive and heavily regulated. It is characterized by high R&D costs, long development timelines, and patent protection.
Positioning
TG Therapeutics is a smaller player competing with larger, more established pharmaceutical companies. Briumvi gives them a competitive advantage in the RMS market segment.
Total Addressable Market (TAM)
The TAM for multiple sclerosis therapies is estimated at $25-30 billion annually. TG Therapeutics' is focused on carving out share within the RMS sub-segment.
Upturn SWOT Analysis
Strengths
- FDA Approved Product (Briumvi)
- Focused Therapeutic Areas
- Experienced Management Team
- Novel Antibody Technology
Weaknesses
- Limited Product Portfolio
- High Debt Levels
- Reliance on Single Product Revenue
- Smaller Commercial Infrastructure Compared to Competitors
Opportunities
- Expansion of Briumvi into New Indications
- Strategic Partnerships and Acquisitions
- Growth in the Autoimmune Disease Market
- Positive Clinical Trial Results
Threats
- Competition from Established Pharmaceutical Companies
- Regulatory Hurdles
- Patent Expiry
- Unfavorable Reimbursement Policies
- Adverse Events or Safety Concerns with Briumvi
Competitors and Market Share
Key Competitors
- RHHBY
- NVS
Competitive Landscape
TG Therapeutics faces strong competition from larger pharmaceutical companies. While Briumvi offers a novel mechanism of action, competitors have established market presence and strong brand recognition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial successes and regulatory approvals.
Future Projections: Future growth is dependent on the commercial success of Briumvi and the advancement of other pipeline candidates. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include the commercial launch of Briumvi, and continued clinical trials in autoimmune disease.
Summary
TG Therapeutics is a biotechnology company with one approved product, Briumvi, targeting the RMS market. The company faces strong competition and relies heavily on the success of Briumvi. Future growth depends on expanding Briumvi's indications, securing strategic partnerships, and overcoming regulatory and competitive hurdles. High debt levels and reliance on single product revenues remain significant challenges.
Similar Companies
- RHHBY
- NVS
- BMY
- VRX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is subject to change and may not be entirely accurate. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TG Therapeutics Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 1995-12-14 | Chairman, CEO & President Mr. Michael S. Weiss Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 338 | Website https://www.tgtherapeutics.com |
Full time employees 338 | Website https://www.tgtherapeutics.com | ||
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.